SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02955407

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Genetic Predisposition for Reduced Back Muscle Strength and Back Muscle Endurance in Patients With Chronic Non-specific Low Back Pain

Patients with inflammatory back pain were shown to differ from healthy controls in genotype of the Angiotensin-converting enzyme (ACE), which regulates vasoconstriction/-dilatation. The aim of this study is to investigate whether genetic reduction of muscle perfusion might be a pathophysiological pathway of how genes influence chronic non-specific low back pain (LBP).

NCT02955407 Low Back Pain
MeSH: Back Pain Low Back Pain Disease Susceptibility Genetic Predisposition to Disease
HPO: Back pain Low back pain

1 Interventions

Name: no intervention

Description: observational case-control study

Type: Other

Controls without low back pain Low back pain patients


Primary Outcomes

Measure: Polymorphism ACE Gene

Time: baseline

Measure: Polymorphism Tenascin Gene

Time: baseline

Secondary Outcomes

Measure: Back muscle endurance in Sorensen test

Time: baseline

Time Perspective: Cross-Sectional

Case-Control


There is one SNP

SNPs


1 rs2104772

- Anti-adhesive extracellular matrix protein Tenascin-C: gene polymorphism rs2104772 The goals of this study are to investigate whether these genotypes correlate with 1) endurance of back muscles, 2) comorbidities such as asthma and diabetes and 3) the risk for LBP as assessed by a LBP-classification tool.



HPO Nodes


HPO:
Back pain
Genes 48
EMD HGD LMNA DLL3 PDGFB ATP7B CLCN7 VANGL1 TP53 TMEM43 SEC63 PLEKHM1 SMAD4 CAPN3 SYNE1 MESP2 BRCA2 SMARCB1 ALDH18A1 SUFU PRKCSH FHL1 PALB2 LMNA LRP5 LMX1B NAB2 TCIRG1 PALLD FHL1 NF2 HELLPAR SPAST SYNE2 VCP CFI TBX6 HLA-B BRCA1 STAT6 CFH PRKCSH HTRA1 FLI1 CD46 CDKN2A KRAS VCP
Low back pain
Genes 6
HTRA1 SPAST ALDH18A1 NAB2 TBX6 STAT6